{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T21:07:55Z","timestamp":1764364075966,"version":"3.44.0"},"reference-count":86,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Qual Saf"],"accepted":{"date-parts":[[2011,4,1]]},"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare three methods of guideline development, to see whether using alternative evidence-based methods resulted in variation of recommendations for treating actinic keratosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Method 1 followed a standard multiple session evidence-based approach with a working group. In method 2 recommendations were formulated by a working group during a 2-day conference. Method 3 used one epidemiologist to summarise the evidence and one dermatologist to make clinical recommendations afterwards. Graded recommendations and levels of evidence were compared per therapy across three draft guidelines. The primary outcome was the extent of accordance or discordance. Secondary outcomes were total costs and time period necessary to make a draft guideline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Therapeutic recommendations and levels of evidence differed in some occasions. However, intraclass correlations between levels of evidence were significant (method 1 vs 2: p=0.003; method 1 vs 3: p&lt;0.001). Regarding recommendation variation method 1 and method 2 correlated significant at 0.755 (p=0.001). Method 1 versus 3 and method 2 versus 3 also showed significant, but lower, correlation coefficients (respectively, 0.493 (p=0.026) and 0.673 (p=0.007)). Method 3 was the cheapest and quickest (24\u2008770 euro and 4\u2005months) and method 1 was the most expensive and slowest method (\u20ac48\u2008100 euro and 14\u2005months).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The value of a guideline using alternative evidence-based methods seems to at least equal that of a guideline composed in multiple sessions, that is, for topics with a monodisciplinary character and a relatively small number of conducted trials. In addition, the presented alternatives were more time- and cost-efficient.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjqs.2010.050443","type":"journal-article","created":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T00:27:42Z","timestamp":1306456062000},"page":"832-841","source":"Crossref","is-referenced-by-count":6,"title":["Prospective comparison of three guideline development methods for treatment of actinic keratosis"],"prefix":"10.1136","volume":"20","author":[{"given":"Rinke J","family":"Borgonjen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannes J","family":"van Everdingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathelijne M","family":"Bik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariska K","family":"Tuut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis I","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2011,5,26]]},"reference":[{"key":"2025090411172474000_20.10.832.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05621.x"},{"key":"2025090411172474000_20.10.832.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00339.x"},{"key":"2025090411172474000_20.10.832.3","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103342"},{"key":"2025090411172474000_20.10.832.4","unstructured":"Dutch Clinical Practice Guideline Actinic Keratosis. http:\/\/www.huidarts.info\/documents\/?v=2&id=193 (accessed 24 Nov 2010)."},{"key":"2025090411172474000_20.10.832.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-9-709"},{"key":"2025090411172474000_20.10.832.6","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/15.1.31"},{"key":"2025090411172474000_20.10.832.7","unstructured":"Quaedvlieg PFJ Ostertag JU de Kort JML . Evidence based treatments of actinic keratoses: a systematic review of efficacy. J Dermatol Treat. In press."},{"key":"2025090411172474000_20.10.832.8","doi-asserted-by":"publisher","DOI":"10.1016\/1076-0512(95)00428-9"},{"key":"2025090411172474000_20.10.832.9","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198707000-00007"},{"key":"2025090411172474000_20.10.832.10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00105-004-0865-6","article-title":"Kryochirurgische behandlung aktinischer keratosen mit evidenzbasierter ubersicht","volume":"56","author":"Zouboulis","year":"2006","journal-title":"Hautarzt"},{"key":"2025090411172474000_20.10.832.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07470.x"},{"key":"2025090411172474000_20.10.832.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"2025090411172474000_20.10.832.13","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119649"},{"key":"2025090411172474000_20.10.832.14","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310012118"},{"key":"2025090411172474000_20.10.832.15","first-page":"235","article-title":"A prospective, randomized study comparing photodynamic therapy with Metvix\u00ae to cryotherapy in actinic keratoses","volume":"14","author":"Szeimies","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090411172474000_20.10.832.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06054.x"},{"key":"2025090411172474000_20.10.832.17","first-page":"161","article-title":"Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy","volume":"4","author":"Gilbert","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"2025090411172474000_20.10.832.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02445.x"},{"key":"2025090411172474000_20.10.832.19","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114288"},{"key":"2025090411172474000_20.10.832.20","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.49"},{"key":"2025090411172474000_20.10.832.21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.41"},{"key":"2025090411172474000_20.10.832.22","first-page":"629","article-title":"Short incubation PDT versus 5-FU in treating actinic keratoses","volume":"2","author":"Smith","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"2025090411172474000_20.10.832.23","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510032887"},{"key":"2025090411172474000_20.10.832.24","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.33"},{"key":"2025090411172474000_20.10.832.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07520.x"},{"key":"2025090411172474000_20.10.832.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04085.x"},{"key":"2025090411172474000_20.10.832.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08450.x"},{"key":"2025090411172474000_20.10.832.28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00042728-200503000-00025","article-title":"Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis","volume":"31","author":"Zelickson","year":"2005","journal-title":"Dermatol Surg"},{"key":"2025090411172474000_20.10.832.29","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20012"},{"key":"2025090411172474000_20.10.832.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2000.99283.x"},{"key":"2025090411172474000_20.10.832.31","doi-asserted-by":"publisher","DOI":"10.1080\/146288301753377852"},{"key":"2025090411172474000_20.10.832.32","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20379"},{"key":"2025090411172474000_20.10.832.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32046.x"},{"key":"2025090411172474000_20.10.832.34","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690140060009"},{"key":"2025090411172474000_20.10.832.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1076-0512(98)00079-X"},{"key":"2025090411172474000_20.10.832.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1076-0512(97)00008-3"},{"key":"2025090411172474000_20.10.832.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70542-0"},{"key":"2025090411172474000_20.10.832.38","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-005-0148-6"},{"key":"2025090411172474000_20.10.832.39","first-page":"335","article-title":"Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis","volume":"70","author":"Jorizzo","year":"2002","journal-title":"Cutis"},{"key":"2025090411172474000_20.10.832.40","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.7.813"},{"key":"2025090411172474000_20.10.832.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80012-1"},{"key":"2025090411172474000_20.10.832.42","first-page":"22","article-title":"Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks","volume":"70","author":"Weiss","year":"2002","journal-title":"Cutis"},{"key":"2025090411172474000_20.10.832.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07942.x"},{"key":"2025090411172474000_20.10.832.44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2003.00003.x"},{"key":"2025090411172474000_20.10.832.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.030"},{"key":"2025090411172474000_20.10.832.46","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.4.467"},{"key":"2025090411172474000_20.10.832.47","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701818870"},{"key":"2025090411172474000_20.10.832.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.010"},{"key":"2025090411172474000_20.10.832.49","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.11.1498"},{"key":"2025090411172474000_20.10.832.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.022"},{"key":"2025090411172474000_20.10.832.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08218.x"},{"key":"2025090411172474000_20.10.832.52","first-page":"58","article-title":"Innovative uses of imiquimod","volume":"4","author":"Vender","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"2025090411172474000_20.10.832.53","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700264"},{"key":"2025090411172474000_20.10.832.54","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.27749"},{"key":"2025090411172474000_20.10.832.55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00635.x"},{"key":"2025090411172474000_20.10.832.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1997.tb01693.x"},{"key":"2025090411172474000_20.10.832.57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04561.x"},{"key":"2025090411172474000_20.10.832.58","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"2025090411172474000_20.10.832.59","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01324.x"},{"key":"2025090411172474000_20.10.832.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70054-0"},{"key":"2025090411172474000_20.10.832.61","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.451"},{"key":"2025090411172474000_20.10.832.62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(82)91393-9","article-title":"Etretinate in treatment of actinic keratosis. A double-blind crossover study","volume":"1","author":"Moriarty","year":"1982","journal-title":"Lancet"},{"key":"2025090411172474000_20.10.832.63","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01831-0"},{"key":"2025090411172474000_20.10.832.64","doi-asserted-by":"publisher","DOI":"10.1080\/09546630152696314"},{"key":"2025090411172474000_20.10.832.65","doi-asserted-by":"publisher","DOI":"10.1159\/000018407"},{"key":"2025090411172474000_20.10.832.66","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70113-G"},{"key":"2025090411172474000_20.10.832.67","first-page":"1281","article-title":"Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine","volume":"9","author":"Alberts","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025090411172474000_20.10.832.68","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.6.829"},{"key":"2025090411172474000_20.10.832.69","first-page":"335","article-title":"Actinic keratosis: how to differentiate the good from the bad ones?","volume":"16","author":"Quaedvlieg","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2025090411172474000_20.10.832.70","doi-asserted-by":"crossref","unstructured":"Lomotan EA Michel G Lin Z . How \u201cshould\u201d we write guideline recommendations? Interpretation of deontic terminology in clinical practice guidelines: survey of the health services community. Qual Saf Health Care. Published Online First: 10 August 2010. doi:10.1136\/qshc.2009.032565.","DOI":"10.1136\/qshc.2009.032565"},{"key":"2025090411172474000_20.10.832.71","unstructured":"Dutch CBO Guideline Manual. http:\/\/www.cbo.nl\/thema\/Richtlijnen\/EBRO-handleiding\/6-Schrijven-van-teksten\/#6.4 (accessed 24 Nov 2010)."},{"key":"2025090411172474000_20.10.832.72","first-page":"426","article-title":"Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists","volume":"159","author":"Wakkee","year":"2008","journal-title":"Br J Dermatol"},{"key":"2025090411172474000_20.10.832.73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"2025090411172474000_20.10.832.74","first-page":"503","article-title":"Evidence-based implementation of evidence-based medicine","volume":"25","author":"Grol","year":"1999","journal-title":"Jt Comm J Qual Improv"},{"key":"2025090411172474000_20.10.832.75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07692.x"},{"key":"2025090411172474000_20.10.832.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.006"},{"key":"2025090411172474000_20.10.832.77","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2025090411172474000_20.10.832.78","doi-asserted-by":"publisher","DOI":"10.2307\/2094540"},{"key":"2025090411172474000_20.10.832.79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7517.631"},{"key":"2025090411172474000_20.10.832.80","first-page":"1","article-title":"Systems to rate the strength of scientific evidence","volume":"47","author":"West","year":"2002","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"2025090411172474000_20.10.832.81","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.12.1.18"},{"key":"2025090411172474000_20.10.832.82","unstructured":"http:\/\/www.g-i-n.net\/ (accessed 24 Nov 2010)."},{"key":"2025090411172474000_20.10.832.83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025090411172474000_20.10.832.84","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39493.646875.AE"},{"key":"2025090411172474000_20.10.832.85","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-5-23"},{"key":"2025090411172474000_20.10.832.86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs.2010.043257"}],"container-title":["BMJ Quality &amp; Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjqs.2010.050443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:21:32Z","timestamp":1757010092000},"score":1,"resource":{"primary":{"URL":"https:\/\/qualitysafety.bmj.com\/lookup\/doi\/10.1136\/bmjqs.2010.050443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,26]]},"references-count":86,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,9,21]]},"published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1136\/bmjqs.2010.050443"],"URL":"https:\/\/doi.org\/10.1136\/bmjqs.2010.050443","relation":{},"ISSN":["2044-5415","2044-5423"],"issn-type":[{"type":"print","value":"2044-5415"},{"type":"electronic","value":"2044-5423"}],"subject":[],"published":{"date-parts":[[2011,5,26]]}}}